Cargando…

Intravitreal rituximab for the treatment of a secondary intraocular relapse of a large B-cell lymphoma

PURPOSE: To report a rare case of secondary intraocular lymphoma treated with intravitreal rituximab, following pars plana vitrectomy. OBSERVATIONS: A 74-year-old female with history of parotid gland large B-cell lymphoma presented bilateral intraocular recurrence 10 years after the onset of the pri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Echegaray, Jose J., Llop, Stephanie, Sepulveda, Melissa, Velez-Rosario, Roman, Perez, Noel, Oliver, Armando L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2018
Materias:	Case report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5861753/ https://www.ncbi.nlm.nih.gov/pubmed/29577096 http://dx.doi.org/10.1016/j.ajoc.2018.01.032

Ejemplares similares

Intraocular inflammation secondary to intravitreal brolucizumab treated successfully with Sub-Tenon triamcinolone: A case report
por: Kurup, Shree K., et al.
Publicado: (2022)

A Case of Primary Intraocular Lymphoma Treated by Intravitreal Methotrexate
por: Kim, Eunah, et al.
Publicado: (2009)

Intraocular lymphoma as relapse after chemotherapy for primary breast diffuse large B-cell lymphoma
por: Matsuo, Toshihiko, et al.
Publicado: (2018)

Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma
por: Vacirca, Jeffrey L., et al.
Publicado: (2013)

Intravitreal Injections of Bevacizumab: The Impact of Needle Size in Intraocular Pressure and Pain
por: Loureiro, Mónica, et al.
Publicado: (2017)

The Efficacy and Safety of Lenalidomide plus Rituximab in an Orbital Relapse of Diffuse Large B-Cell Lymphoma
por: Palmieri, R., et al.
Publicado: (2019)

Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma
por: Murayama, Kayoko, et al.
Publicado: (2022)

Effect of Intravitreal Methotrexate and Rituximab on Interleukin-10 Levels in Aqueous Humor of Treated Eyes with Vitreoretinal Lymphoma
por: Raja, Harish, et al.
Publicado: (2013)

Phase Ib study of avadomide (CC‐122) in combination with rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma and follicular lymphoma
por: Nastoupil, Loretta J., et al.
Publicado: (2022)

Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma
por: Nastoupil, Loretta J., et al.
Publicado: (2022)

Lenalidomide plus rituximab Vs rituximab alone in relapsed or refractory indolent lymphoma: A cost‐effectiveness analysis
por: Zhang, Peng‐Fei, et al.
Publicado: (2020)

Intravitreal triamcinolone acetonide: Pattern of secondary intraocular pressure rise and possible risk factors
por: Bashshur, Ziad F, et al.
Publicado: (2008)

Intravitreal bevacizumab as therapy for refractory neovascular glaucoma secondary to iris metastasis of breast carcinoma
por: Vale, Stephanie, et al.
Publicado: (2018)

Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma
por: Lee, Yong-Pyo, et al.
Publicado: (2021)

Electrophysiological Monitoring of Focal and Entire Retinal Function during Treatment with Intravitreal Methotrexate for Intraocular Lymphoma
por: Matsushima, Takashi, et al.
Publicado: (2021)

Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma
por: Borgerding, Andrea, et al.
Publicado: (2009)

Urelumab alone or in combination with rituximab in patients with relapsed or refractory B‐cell lymphoma
por: Timmerman, John, et al.
Publicado: (2020)

Cd20 Expression and Effects on Outcome of Relapsed/Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab
por: Rasheed, Afshan Asghar, et al.
Publicado: (2018)

A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B‐cell lymphoma
por: Terui, Yasuhito, et al.
Publicado: (2021)

P1163: ZANUBRUTINIB PLUS RITUXIMAB AND LENALIDOMIDE (ZR2) FOR RELAPSED AND REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
por: Zhang, Xiyuan, et al.
Publicado: (2023)

Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial
por: Zinzani, Pier Luigi, et al.
Publicado: (2012)

AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma
por: Leonard, John P., et al.
Publicado: (2019)

Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma
por: Feldman, Tatyana, et al.
Publicado: (2014)

Neoehrlichia mikurensis Causing Thrombosis and Relapsing Fever in a Lymphoma Patient Receiving Rituximab
por: Sjöwall, Johanna, et al.
Publicado: (2021)

Rituximab in the Treatment of Acquired Angioedema Secondary to Marginal Zone Lymphoma of the Spleen
por: Wu, Kathie, et al.
Publicado: (2023)

Copanlisib plus rituximab combination therapy vs. rituximab monotherapy for relapsed indolent non-Hodgkin lymphoma: a cost-effectiveness analysis
por: Tang, Xiao, et al.
Publicado: (2022)

Phase II study of dose‐adjusted gemcitabine, dexamethasone, cisplatin, and rituximab in elderly relapsed diffuse large B‐cell lymphoma patients
por: Yamasaki, Satoshi, et al.
Publicado: (2020)

Phase 1b Dose-finding Study of Venetoclax With Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
por: Petrillo, Alessandra, et al.
Publicado: (2022)

Poor clinical outcome of relapsed/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximab
por: Saburi, Masuho, et al.
Publicado: (2023)

Phase Ib study of combinations of avadomide (CC‐122), CC‐223, CC‐292, and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma
por: Ribrag, Vincent, et al.
Publicado: (2022)

Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab
por: Boyer-Suavet, Sonia, et al.
Publicado: (2020)

Intravitreal triamcinolone for intraocular inflammation and associated macular edema
por: Couch, Steven M, et al.
Publicado: (2009)

Intraocular Pressure Following Intravitreal Injection of Triamcinolone Acetonide
por: Ansari, Ejaz A, et al.
Publicado: (2008)

Immediate effect of intravitreal injection of bevacizumab on intraocular pressure
por: Lemos-Reis, Ricardo, et al.
Publicado: (2014)

Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma
por: Matasar, Matthew J., et al.
Publicado: (2021)

Intravitreal Ampicillin Sodium for Antibiotic-Resistant Endophthalmitis: Streptococcus uberis First Human Intraocular Infection Report
por: Velez-Montoya, Raul, et al.
Publicado: (2010)

Rituximab maintenance in relapsed or refractory follicular non-Hodgkin’s lymphoma: the evidence of its therapeutic value
por: Ardeshna, Kirit M.
Publicado: (2007)

Intraocular pressure fluctuation following intravitreal dexamethasone implant and incidence of secondary ocular hypertension: a Zambian perspective
por: Raj, Pallavi, et al.
Publicado: (2021)

Phase I/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B cell lymphoma
por: Dührsen, Ulrich, et al.
Publicado: (2021)

Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey
por: Dal, Mehmet Sinan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lom0lceq53rbkflv3jo1jha8hu